This document summarizes a monograph by the Journal of the National Cancer Institute on the latest state of the science around single-dose HPV vaccination. It includes follow-up from studies that informed WHO’s 2022 endorsement of a single-dose schedule for HPV vaccines, as well as new studies on topics such as durability of protection, effectiveness and health impact across diverse socioeconomic contexts, implementation, and cervical cancer screening integration.

Taken together, the papers in this monograph add to and reinforce earlier findings: across multiple geographies, single-dose HPV vaccination provides strong protection against cancer-causing HPV infection, while also providing opportunities to reduce ongoing program costs and expand coverage.